Soybean Bowman‐Birk protease inhibitor (BBI) and genistein, two biological compounds from soybean, are well‐known for their anti‐inflammatory, antioxidant, and anticancer activities. The aim of this study was designing a BBI‐genistein… Click to show full abstract
Soybean Bowman‐Birk protease inhibitor (BBI) and genistein, two biological compounds from soybean, are well‐known for their anti‐inflammatory, antioxidant, and anticancer activities. The aim of this study was designing a BBI‐genistein conjugate and then investigating its protective effect on lipopolysaccharide (LPS)‐induced inflammation in BALB/c mice, compared with the effects of combination of BBI and genistein. BBI was purified from soybean and the BBI‐genistein conjugate was synthesized. The BALB/c mice were intraperitoneally treated 2 hours before LPS induction. Our results showed that treatment with the combination of BBI and genistein greatly led to more reduced serum levels of tumor necrosis factor (TNF)‐α and interferon (IFN)‐γ compared with the treatments of BBI alone, the BBI‐genistein conjugate, and genistein alone, respectively. Moreover, the expression of TNF‐α and IFN‐γ in the splenocytes was significantly downregulated along with improving host survival against the LPS‐induced lethal endotoxemia in the same way. Our data support a new combined therapy using BBI and genistein, as natural anti‐inflammatory agents, to develop a new drug for inflammatory diseases.
               
Click one of the above tabs to view related content.